Connect with us
This year, one of the main headaches for managers in the sector will be inflation. GSK and Novartis plan to carry out a double-digit price increase...
Novartis has the worst rating in the European pharmaceutical industry, while AstraZeneca downgrades its expectations from exceptional to neutral. Credit Suisse has also analyzed the Spanish...
The Swiss pharmaceutical company plans to lay off 8,000 workers worldwide, equivalent to 7.7% of the total workforce. The Novartis job cuts are part of the...
Spinal muscular atrophy is a rare disease caused by an alteration in the SMN1 gene which leads to progressive muscle weakness, as the lack of SMN...
A compassionate use program that included 12 ARDS patients associated with COVID-19 was launched in March. The patients were in mechanical ventilation. The therapy was associated...
The global slowdown in economic growth has so far left Roche and Novartis' businesses untouched. Both drug manufacturers, based in Basel, are currently growing significantly faster...
Parents of children with serious health conditions are facing high costs of healthcare.
Effectively ending their self-imposed halt this year, drugmakers will start the new year with drug price increases.
Teva initially got the chance to launch its drug called fremanezumab before Aimovig, but the opportunity slipped away when there was a delay in its FDA...